BiotechTube
Agathos Biologics

Agathos Biologics

Boston, United States· Est.
agathos.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $8.7M

Overview

Agathos Biologics is a private, pre-revenue biotech firm developing an ethical cell line platform for biomanufacturing, specifically targeting the recombinant adeno-associated virus (rAAV) production market for gene therapies. Its core technology, the AE1-BHK cell line, is offered as an alternative to controversial HEK293 cells, aiming to address scalability and ethical concerns in the industry. The company is led by a seasoned team with deep experience in gene therapy and biomanufacturing, and it is actively pursuing internal therapeutic programs and collaborations.

Gene TherapyImmunology

Technology Platform

AE1-BHK ethical cell line for recombinant AAV (rAAV) production and biomanufacturing; biological systems for therapeutic payload delivery.

Funding History

2
Total raised:$8.7M
Seed$4.5M
Seed$4.2M

Opportunities

The company addresses a major scalability bottleneck and ethical concern in the high-growth gene therapy manufacturing market.
Its ethical positioning could attract partners and customers seeking morally aligned supply chains and potentially mitigate public distrust in biologics.

Risk Factors

Primary risks include overcoming industry inertia to adopt a new manufacturing cell line, potential polarization from its ethical branding, and competition from large, well-capitalized bioprocessing companies that could develop similar technologies.

Competitive Landscape

Agathos competes with established bioprocessing giants (e.g., Thermo Fisher, Sartorius) and CDMOs using HEK293 and other cell lines. Its differentiation is the explicit ethical origin of its BHK-derived platform and its focus on solving scalability for AAV production, a niche within the broader cell line market.

More companies in Biologics / Biosimilars →More companies in United States →